[1]陈时锦 郭晓萍.WISP1在糖尿病中的作用[J].国际内分泌代谢杂志,2019,39(06):419-421.[doi:10.3760/cma.j.issn.1673-4157.2019.06.014]
　Chen Shijin,Guo Xiaoping.Role of WISP1 in diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2019,39(06):419-421.[doi:10.3760/cma.j.issn.1673-4157.2019.06.014]
点击复制

WISP1在糖尿病中的作用()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
39
期数:
2019年06期
页码:
419-421
栏目:
综述
出版日期:
2019-11-20

文章信息/Info

Title:
Role of WISP1 in diabetes mellitus
作者:
陈时锦1 郭晓萍2
1桂林力源粮油食品集团有限公司研究院 541100; 2广西医科大学实验动物中心,南宁 530021
Author(s):
Chen Shijin1;  Guo Xiaoping2
1Research Institute of Guilin Liyuan Grain, Oil and Food Group Co., Ltd, Guilin 541100, China; 2Guangxi Medical University Laboratory Animal Center, Nanning 530021, China
关键词:
WISP1;  糖尿病;  生物学标志物;  炎症;  胰岛素抵抗
Keywords:
WISP1;  Diabetes mellitus;  Biological markers;  Inflammation;  Insulin resistance
DOI:
10.3760/cma.j.issn.1673-4157.2019.06.014
摘要:
Wnt1诱导信号通路蛋白(WISP1)是一种代谢相关的新型脂肪因子,属于分泌型糖蛋白,参与多种细胞信号转导通路。一方面,WISP1通过磷酸化c-Jun氨基末端激酶(JNK)炎性反应信号通路诱导炎性反应发生; 另一方面,WISP1通过抑制胰岛素信号通路和糖原合成酶激酶的磷酸化来损害胰岛素的作用; 此外,WISP1通过骨形态发生蛋白3依赖性信号通路促进脂肪生成和甘油三酯的累积。糖尿病患者中血清WISP1水平显著上调,体外和体内研究证实,WISP1水平下降可改善炎性反应和小鼠糖耐量,减少胰岛素抵抗。因此,WISP1参与炎性反应、血糖和胰岛素抵抗的调控过程,与糖尿病的发生密切相关,有望成为糖尿病的生物标志物。
Abstract:
Wnt1 inducible signaling pathway protein 1(WISP1)is a novel metabolic adipokine, which belongs to secretory glycoprotein and participates in many cell signaling pathways. On the one hand, WISP1 significantly induces inflammation by phosphorylating c-Jun N-terminal kinase(JNK)inflammation signaling pathway; on the other hand, WISP1 impairs the effects of insulin by inhibiting insulin signaling pathway and glycogen synthase kinase phosphorylation. Moreover, WISP1 promotes adipogenesis and the accumulation of triglyceride through bone morphogenetic protein-dependent signaling pathway. It has been reported that serum WISP1 level was significantly increased in diabetic patients. It was confirmed that the decrease of WISP1 could improve inflammation and glucose tolerance, and reduce insulin resistance in mice by vitro and vivo experiments. Therefore, WISP1 is involved in the regulation of inflammation, blood sugar and insulin resistance, which is closely related to the occurrence of diabetes mellitus and is expected to become a biomarker of diabetes mellitus.

参考文献/References:

[1] Berschneider B,Königshoff M. WNT1 inducible signaling pathway protein 1(WISP1): a novel mediator linking development and disease[J].Int J Biochem Cell Biol,2011,43(3):306-309.DOI:10.1016/j.biocel.2010.11.013.
[2] Hashimoto Y,Shindo-Okada N,Tani M,et al.Identification of genes differentially expressed in association with metastatic potential of K-1735 murine melanoma by messenger RNA differential display[J].Cancer Res,1996,56(22):5266-5271.
[3] Zuo GW,Kohls CD,He BC,et al.The CCN proteins: important signaling mediators in stem cell differentiation and tumorigenesis[J].Histol Histopathol,2010,25(6):795-806.DOI:10.14670/HH-25.795.
[4] Maiese K,Chong ZZ,Shang YC,et al.Targeting disease through novel pathways of apoptosis and autophagy[J].Expert Opin Ther Targets,2012,16(12):1203-1214.DOI:10.1517/14728222.2012.719499.
[5] Xu L,Corcoran RB,Welsh JW,et al.WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene[J].Genes Dev,2000,14(5):585-595.
[6] Deng W,Fernandez A,McLaughlin SL,et al.WNT1-inducible signaling pathway protein 1(WISP1/CCN4)stimulates melanomainvasion and metastasis by promoting the epithelial-mesenchymal transition[J].J Biol Chem,2019,294(14):5261-5280.DOI:10.1074/jbc.RA118.006122.
[7] Murahovschi V,Pivovarova O,Ilkavets I,et al.WISP1 is a novel adipokine linked to inflammation in obesity[J].Diabetes,2015,64(3):856-866.DOI:10.2337/db14-0444.
[8] Barchetta I,Cimini FA,Capoccia D,et al.WISP1 is a marker of systemic and adipose tissue inflammation in dysmetabolic subjects with or without type 2 diabetes[J].J Endocr Soc,2017,1(6):660-670.DOI:10.1210/js.2017-00108.
[9] Wang AR,Yan XQ,Zhang C,et al.Characterization of wnt1-inducible signaling pathway protein-1 in obese children and adolescents[J].Curr Med Sci,2018,38(5):868-874.DOI:10.1007/s11596-018-1955-5.
[10] Jung TW,Kang C,Goh J,et al.WISP1 promotes non-alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling[J].J Cell Physiol,2018,233(8):6077-6087.DOI:10.1002/jcp.26449.
[11] Sahin Ersoy G,Altun Ensari T,Subas S,et al.WISP1 is a novel adipokine linked to metabolic parameters in gestational diabetes mellitus[J].J Matern Fetal Neonatal Med,2017,30(8):942-946.DOI:10.1080/14767058.2016.1192118.
[12] Hörbelt T,Tacke C,Markova M,et al.The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes[J].Diabetologia,2018,61(9):2054-2065.DOI:10.1007/s00125-018-4636-9.
[13] Tacke C,Aleksandrova K,Rehfeldt M,et al.Assessment of circulating Wnt1 inducible signalling pathway protein 1(WISP-1)/CCN4 as a novel biomarker of obesity[J].J Cell Commun Signal,2018, 12(3):539-548.DOI:10.1007/s12079-017-0427-1.
[14] Wang S,Chong ZZ,Shang YC,et al. WISP1(CCN4)autoregulates its expression and nuclear trafficking of β-catenin during oxidant stress with limited effects upon neuronal autophagy[J].Curr Neurovasc Res,2012,9(2):91-101.
[15] Cernea M,Tang W,Guan H,et al.Wisp1 mediates Bmp3-stimulated mesenchymal stem cell proliferation[J].J Mol Endocrinol,2016,56(1):39-46.DOI:10.1530/JME-15-0217.

相似文献/References:

[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
　Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
　Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(06):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
　Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(06):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制 ——2014年美国糖尿病协会“杰出科学成就奖” 演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
　Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(06):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
　Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(06):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
　Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(06):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
　Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(06):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
　Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(06):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
　Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(06):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
　Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(06):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]

备注/Memo

备注/Memo:
通信作者:郭晓萍,Email:331760518@qq.com
Corresponding author:Guo Xiaoping, Email:331760518@qq.com
基金项目:广西省自然科学基金(2018GXNSFBA281002); 广西高校中青年教师基础能力提升项目(2018KY0108)
Fund program:Natural Science Foundation of Guangxi Province of China(2018GXNSFBA281002); Basic Competence Promotion Project for Young and Middle-aged Teachers in Guangxi Universities(2018KY0108)
更新日期/Last Update: 2019-11-20